US Food and Drug Administration (FDA) approved new this friday nasal preparation from pfizer for migraines, the company said.

Medicine, Forbidden was the first to use the route nasal application to relieve the most common symptoms headachesuch as headache or sensitivity to light.

“The FDA approval of Zavzpret is an important step forward for people with migraine who need painless treatment and prefer alternatives to oral medications,” said Pfizer commercial director Angela Hwang.

#VIOLATION: FDA approved vegepant for the emergency treatment of migraine with or without aura in adults. A therapeutic called Zavzpret becomes the first and only CGRP nasal spray available for patients with #migraine.

Details: https://t.co/mQJcHKA8cr

— NeurologyLive® (@neurology_live) March 10, 2023

“The FDA has approved Zavegepant for the treatment of migraine in adults. The therapeutic product, sold under the name Zavzpret, is the first and only CGRP nasal spray for the treatment of migraine.”

INwalked Twitter @Neurology_live

The drug showed in phase 3 trials, relieve pain Only for 15 minutes And end completely with symptoms the worst of diseases in two hoursthe company assured.

Although patients in clinical studies generally showed good tolerance to the drug, 2% of those who received it experienced some intolerance. secondary effecte.g. taste disorder nausea or vomiting.

In an interview with EFE, Francesca Fiorito-Torres, a migraine doctor, explained that Pfizer’s new drug could be great option For people who experience nausea or vomiting when taking oral medications.

Fiorito-Torres made it clear that “there is a place for everything in the migraine world”, but ventured to suggest that nasal method will eventually become ruleas it does medicine There is peak fasteralthough it has not yet been compared to other migraine medications.

According to Pfizer, migraine touches on 1000000000 people worldwide and nearly 40 million Americans, especially women, who are three times more likely to suffer from them than men.